Wuyan Zhang

916 total citations
12 papers, 121 citations indexed

About

Wuyan Zhang is a scholar working on Immunology, Rheumatology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Wuyan Zhang has authored 12 papers receiving a total of 121 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 5 papers in Rheumatology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Wuyan Zhang's work include Biosimilars and Bioanalytical Methods (6 papers), Rheumatoid Arthritis Research and Therapies (5 papers) and Pharmaceutical studies and practices (4 papers). Wuyan Zhang is often cited by papers focused on Biosimilars and Bioanalytical Methods (6 papers), Rheumatoid Arthritis Research and Therapies (5 papers) and Pharmaceutical studies and practices (4 papers). Wuyan Zhang collaborates with scholars based in United States, United Kingdom and Germany. Wuyan Zhang's co-authors include David A. Katz, Carol Cronenberger, Roy Fleischmann, Wei Liu, Nicholas J. Greco, Andreas Meier, Robert Lenz, Gerard J. Marek, Ivana Vranić and Rieke Alten and has published in prestigious journals such as New England Journal of Medicine, Frontiers in Immunology and Arthritis Research & Therapy.

In The Last Decade

Wuyan Zhang

12 papers receiving 116 citations

Peers

Countries citing papers authored by Wuyan Zhang

Since Specialization

Citations

This map shows the geographic impact of Wuyan Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wuyan Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wuyan Zhang more than expected).

Fields of papers citing papers by Wuyan Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wuyan Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wuyan Zhang. The network helps show where Wuyan Zhang may publish in the future.

Co-authorship network of co-authors of Wuyan Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Wuyan Zhang. A scholar is included among the top collaborators of Wuyan Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wuyan Zhang. Wuyan Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Antidrug antibodies to adalimumab do not associate with immunologically related adverse events 2025 ·Frontiers in Immunology ·Sophie Tourdot, (unknown), Donna S. Cox, Chunhua Cai, Karen Wang, Wuyan Zhang, Christopher Lepsy	3
2	Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19 2024 ·New England Journal of Medicine ·Jennifer Hammond, Carla Yunis, Robert J. Fountaine, Gérald Luscan, Aimee Burr, Wuyan Zhang, Wayne Wisemandle, Holly Soares, Mary Lynn Baniecki, (unknown), (unknown), Rienk Pypstra, James M. Rusnak	6
3	Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study 2023 ·The Lancet Rheumatology ·Roy Fleischmann, (unknown), Sharad Lakhanpal, (unknown), Donna S. Cox, (unknown), Wuyan Zhang, Carol Cronenberger, Karen Wang	8
4	Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis 2022 ·Rheumatology and Therapy ·Roy Fleischmann, (unknown), Wuyan Zhang, (unknown), Ivana Vranić, Carol Cronenberger, Eva Dokoupilová	4
5	Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis 2022 ·RMD Open ·Jonathan Kay, (unknown), (unknown), Wuyan Zhang, Min Zhang, Noriko Iikuni, (unknown)	1
6	Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial 2021 ·Arthritis Research & Therapy ·Roy Fleischmann, (unknown), (unknown), Carol Cronenberger, Ivana Vranić, Wuyan Zhang, Rieke Alten	12
7	Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293 2021 ·RMD Open ·Roy Fleischmann, (unknown), (unknown), Carol Cronenberger, Ivana Vranić, Wuyan Zhang, Rieke Alten	13
8	Efficacy and safety evaluation of HSD‐1 inhibitor ABT‐384 in Alzheimer's disease 2014 ·Alzheimer s & Dementia ·Gerard J. Marek, David A. Katz, Andreas Meier, Nicholas J. Greco, Wuyan Zhang, Wei Liu, Robert Lenz	36
9	Comparison of Paricalcitol With Maxacalcitol Injection in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism 2014 ·Therapeutic Apheresis and Dialysis ·Tadao Akizawa, Takashi Akiba, Hideki Hirakata, Eriko Kinugasa, Yoshihiro Tominaga, Masafumi Fukagawa, Keitaro Yokoyama, Wuyan Zhang, Peter G. Linde, Masashi Suzuki	13
10	Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease 2012 ·Ravi Thadhani, Evan Appelbaum, Yili Pritchett, Julia Wenger, Hector Tamez, Ishir Bhan, Rajiv Agarwal, Carmine Zoccali, Christoph Wanner, Donald M. Lloyd‐Jones, Jorge B. Cannata‐Andía, Bruce Thompson, Dennis L. Andress, Wuyan Zhang, David Packham, Bhupinder Singh, Daniel Zehnder, Amil Shah, Warren J. Manning, Scott D. Solomon	10
11	P3‐418: Evaluation of the efficacy and safety of the HSD‐1 inhibitor ABT‐384 in mild‐to‐moderate Alzheimer's disease 2012 ·Alzheimer s & Dementia ·Gerard J. Marek, David A. Katz, Andreas Meier, Nicholas J. Greco, Wuyan Zhang, Wei Liu, Robert Lenz	1
12	The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease 2011 ·Clinical Trials ·Yili Pritchett, (unknown), Yuchiao Chang, Ishir Bhan, Rajiv Agarwal, Carmine Zoccali, Christoph Wanner, Donald M. Lloyd‐Jones, Jorge B. Cannata‐Andía, Bruce Thompson, Evan Appelbaum, Paul Audhya, Dennis L. Andress, Wuyan Zhang, Scott D. Solomon, Warren J. Manning, Ravi Thadhani	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact